A new draft guidance clarifies how the FDA decides when an effect on a surrogate endpoint is reasonably likely to predict clinical benefit. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
